Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes

Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status

“…Dyslipidemia frequently coexisted with T2DM ( 39 ), in which overproduction of very low-density lipoproteins commonly occurs ( 40 ). Dyslipidemia induced lipotoxicity may eventually cause increased lipid accumulation in cardiomyocytes ( 41 ), which may increase the epicardial fat thickness, and impairment in mitochondrial function ( 42 , 43 ), which may alter the myocardial energy metabolism. Evidence showed that increased epicardial fat volume and impaired myocardial glucose uptake are well-established risk factors for myocardial remodeling and diastolic dysfunction ( 44 , 45 ).…”

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

“…A wide range of metabolites in a variety of CHDs have been reported (83)(84)(85), notably acylcarnitines, triacylglycerides, amino-acid related compounds, lipids, and free fatty acids. Accordingly, lipids play an important role in a wide range of cardiovascular diseases, inflammatory processes, atherosclerosis, myocardial infarction, cardiac function, ventricular remodeling, and metabolic diseases that can start at a juvenile age (24). Lipidomic analyses is an expanding field and should also be explored in pediatric HF and CHD (25).…”

“…However, in contrast to adult HF, plasma BNP as clinical biomarker is not yet included in the pediatric HF guidelines and there is no standardized reference cut-off value yet ( 16 , 21 ). Furthermore, in a wide variety of (multi)-Omics studies, several constituents are noteworthy and becoming increasingly popular such as Galectin-3 ( 22 , 23 ), Lipids ( 24 ) and Free Fatty Acids ( 25 , 26 ). We searched for biomarkers with respect to diagnosis and monitoring in specific anatomical types of CHD in the pediatric population, together with a concise description of our own experience in applying plasma BNP as a clinical biomarker in pediatric HF and CHD in the setting of surgical correction.…”

GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis

“…The outstanding character of T2D is the systemic metabolic disturbances including elevated blood glucose and lipid content level ( 2 , 3 ). Glucose toxicity ( 4 , 5 ) and lipid toxicity ( 6 , 7 ) are the two major metabolic insults to those energy-demanding organs such as the heart. We have previously reported that high-glucose environment could significantly induce cardiomyocyte hypertrophy by disturbing mitophagy, indicating the metabolic involvement of cardiac complications of T2D ( 8 ).…”